Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.
作者： Zachary A. Cooper , Dennie T. Frederick , Zain Ahmed , Jennifer A. Wargo
DOI: 10.4161/ONCI.24320
关键词:
摘要: The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment melanoma, even though each these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed existence synergistic interaction between modalities.
sci-hub.se 参考文章(10)
F. Stephen Hodi, Steven J. O'Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B. Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Alfons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M. Vaubel, Gerald P. Linette, David Hogg, Christian H. Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok, Jeffrey S. Weber, Jason Tian, Michael J. Yellin, Geoffrey M. Nichol, Axel Hoos, Walter J. Urba, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine. ,vol. 363, pp. 711- 723 ,(2010) , 10.1056/NEJMOA1003466
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan M. Parker, Shruti Agrawal, Stacie M. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton, Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer The New England Journal of Medicine. ,vol. 366, pp. 2455- 2465 ,(2012) , 10.1056/NEJMOA1200694
James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, Richard A. Scolyer, Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma Clinical Cancer Research. ,vol. 18, pp. 1386- 1394 ,(2012) , 10.1158/1078-0432.CCR-11-2479
Chengwen Liu, Weiyi Peng, Chunyu Xu, Yanyan Lou, Minying Zhang, Jennifer A Wargo, Jie Qing Chen, Haiyan S Li, Stephanie S Watowich, Yan Yang, Dennie Tompers Frederick, Zachary A Cooper, Rina M Mbofung, Mayra Whittington, Keith T Flaherty, Scott E Woodman, Michael A Davies, Laszlo G Radvanyi, Willem W Overwijk, Gregory Lizée, Patrick Hwu, None, BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical Cancer Research. ,vol. 19, pp. 393- 403 ,(2013) , 10.1158/1078-0432.CCR-12-1626
Dennie T. Frederick, Adriano Piris, Alexandria P. Cogdill, Zachary A. Cooper, Cecilia Lezcano, Cristina R. Ferrone, Devarati Mitra, Andrea Boni, Lindsay P. Newton, Chengwen Liu, Weiyi Peng, Ryan J. Sullivan, Donald P. Lawrence, F. Stephen Hodi, Willem W. Overwijk, Gregory Lizée, George F. Murphy, Patrick Hwu, Keith T. Flaherty, David E. Fisher, Jennifer A. Wargo, BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clinical Cancer Research. ,vol. 19, pp. 1225- 1231 ,(2013) , 10.1158/1078-0432.CCR-12-1630
Andrea Boni, Alexandria P. Cogdill, Ping Dang, Durga Udayakumar, Ching-Ni Jenny Njauw, Callum M. Sloss, Cristina R. Ferrone, Keith T. Flaherty, Donald P. Lawrence, David E. Fisher, Hensin Tsao, Jennifer A. Wargo, Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function Cancer Research. ,vol. 70, pp. 5213- 5219 ,(2010) , 10.1158/0008-5472.CAN-10-0118
Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Celeste Lebbe, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven J. O'Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur, Paul B. Chapman, Axel Hauschild, Caroline Robert, John B. Haanen, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation The New England Journal of Medicine. ,vol. 364, pp. 2507- 2516 ,(2011) , 10.1056/NEJMOA1103782
Jahan S. Khalili, Shujuan Liu, Tania G. Rodríguez-Cruz, Mayra Whittington, Seth Wardell, Chengwen Liu, Minying Zhang, Zachary A. Cooper, Dennie T. Frederick, Yufeng Li, Min Zhang, Richard W. Joseph, Chantale Bernatchez, Suhendan Ekmekcioglu, Elizabeth Grimm, Laszlo G. Radvanyi, Richard E. Davis, Michael A. Davies, Jennifer A. Wargo, Patrick Hwu, Gregory Lizée, Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma Clinical Cancer Research. ,vol. 18, pp. 5329- 5340 ,(2012) , 10.1158/1078-0432.CCR-12-1632
Keith T. Flaherty, Jeffery R. Infante, Adil Daud, Rene Gonzalez, Richard F. Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini Kudchadkar, Howard A. Burris, Gerald Falchook, Alain Algazi, Karl Lewis, Georgina V. Long, Igor Puzanov, Peter Lebowitz, Ajay Singh, Shonda Little, Peng Sun, Alicia Allred, Daniele Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey Weber, Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations The New England Journal of Medicine. ,vol. 367, pp. 1694- 1703 ,(2012) , 10.1056/NEJMOA1210093
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott J. Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D. Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. ,vol. 366, pp. 2443- 2454 ,(2012) , 10.1056/NEJMOA1200690